-- First presentation of next-generation and long-acting coagulation Factor VIIa clinical trial results in patients with hemophilia A or B --
SOUTH SAN FRANCISCO, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., a privately held biopharmaceutical company, today announced that data from three of its product candidates will be presented at the International Society on Thrombosis and Haemostatsis (ISTH) Meeting being held in Toronto, Canada from June 20 to 25, 2015. The presentations, being made by Catalyst and its collaborators, are as follows:
Factor VIIa: CB 813d/PF-05280602 is an improved next-generation and long-acting coagulation Factor VIIa variant and Catalyst's most advanced clinical development program.
Safety, Pharmacokinetics and Pharmacodynamics of PF-05280602 (Recombinant FVIIa Variant): Preliminary results from a single ascending dose Phase I study in hemophilia A and B subjects, Gruppo et al.
Abstract #PO266
Wednesday, June 24 from 5:15 to 6:30 p.m. ET (poster presentation)
PF-05280602, a Factor VIIa variant with enhanced in vitro potency compared to wild-type Factor VIIa in hemophilic hemostasis assays, Patel-Hett et al.
Abstract #PO597
Wednesday, June 24 from 5:15 to 6:30 p.m. ET (poster presentation)
A systems biology model for the coagulation network describes biomarker changes observed in a clinical study with FVIIa variant, Hua et al.
Abstract #PO512
Tuesday, June 23 from 6:00 to 7:30 p.m. ET (poster presentation)
Factor IX: CB 2679d/ISU 304 is a next-generation coagulation Factor IX variant that is in advanced preclinical development.
CB-FIX: an improved second generation FIX drug candidate, Madison et al.
Abstract #OR299
Wednesday, June 24 at 8:45 a.m. ET (oral presentation)
Factor Xa: a Factor Xa variant that is in preclinical research
CB-FXa: an improved second generation FXa variant, Madison et al.
Abstract #OR247
Tuesday, June 23 at 2:15 p.m. ET (oral presentation)
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel products based on engineered human proteases to address serious unmet medical needs in multiple high value indications. To date, Catalyst has focused its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration, a condition that can cause visual impairment or blindness. Catalyst's most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d/PF-05280602, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst's lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. Catalyst is privately held and backed by leading venture firms including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Innovation – JJDC, Inc., Morgenthaler Ventures, Rosetta Capital and Sofinnova Ventures. As previously announced, Catalyst has entered into a definitive agreement with Targacept, Inc. (Nasdaq:TRGT) to merge the two companies. The merger is expected to close in the third quarter of 2015. For more information, please visit www.catbio.com.
Help employers find you! Check out all the jobs and post your resume.
SOUTH SAN FRANCISCO, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., a privately held biopharmaceutical company, today announced that data from three of its product candidates will be presented at the International Society on Thrombosis and Haemostatsis (ISTH) Meeting being held in Toronto, Canada from June 20 to 25, 2015. The presentations, being made by Catalyst and its collaborators, are as follows:
Factor VIIa: CB 813d/PF-05280602 is an improved next-generation and long-acting coagulation Factor VIIa variant and Catalyst's most advanced clinical development program.
Safety, Pharmacokinetics and Pharmacodynamics of PF-05280602 (Recombinant FVIIa Variant): Preliminary results from a single ascending dose Phase I study in hemophilia A and B subjects, Gruppo et al.
Abstract #PO266
Wednesday, June 24 from 5:15 to 6:30 p.m. ET (poster presentation)
PF-05280602, a Factor VIIa variant with enhanced in vitro potency compared to wild-type Factor VIIa in hemophilic hemostasis assays, Patel-Hett et al.
Abstract #PO597
Wednesday, June 24 from 5:15 to 6:30 p.m. ET (poster presentation)
A systems biology model for the coagulation network describes biomarker changes observed in a clinical study with FVIIa variant, Hua et al.
Abstract #PO512
Tuesday, June 23 from 6:00 to 7:30 p.m. ET (poster presentation)
Factor IX: CB 2679d/ISU 304 is a next-generation coagulation Factor IX variant that is in advanced preclinical development.
CB-FIX: an improved second generation FIX drug candidate, Madison et al.
Abstract #OR299
Wednesday, June 24 at 8:45 a.m. ET (oral presentation)
Factor Xa: a Factor Xa variant that is in preclinical research
CB-FXa: an improved second generation FXa variant, Madison et al.
Abstract #OR247
Tuesday, June 23 at 2:15 p.m. ET (oral presentation)
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel products based on engineered human proteases to address serious unmet medical needs in multiple high value indications. To date, Catalyst has focused its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration, a condition that can cause visual impairment or blindness. Catalyst's most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d/PF-05280602, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst's lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. Catalyst is privately held and backed by leading venture firms including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Innovation – JJDC, Inc., Morgenthaler Ventures, Rosetta Capital and Sofinnova Ventures. As previously announced, Catalyst has entered into a definitive agreement with Targacept, Inc. (Nasdaq:TRGT) to merge the two companies. The merger is expected to close in the third quarter of 2015. For more information, please visit www.catbio.com.
Help employers find you! Check out all the jobs and post your resume.
